AUG 12·SEC EDGARLow
Leproust Emily M. sold $14.2M of TWST
Leproust Emily M. (Chief Executive Officer) sold 113,318 shares of Twist Bioscience Corp (TWST) at $125.16 ($14.18M total) on 2026-08-10 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Diagnostics & Research
$TWST
Twist Bioscience Corp
Price · $TWSTvia TradingView
AI sentiment · 7d3 articles
- Bullish
- 2
- Neutral
- 1
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $18.9M 9 txs
Finn Patrick John2× · $457K
10b5-1 share of filings33%
Top stories · $TWSTMore →
AUG 11·SEC EDGAR
CHESS ROBERT sold $2.0M of TWST
CHESS ROBERT sold 18,417 shares of Twist Bioscience Corp (TWST) at $110.89 ($2.04M total) on 2026-08-07 under a Rule 10b5-1 trading plan.
AUG 11·247wallst.com
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
Anthropic is reportedly targeting an IPO in September or early October 2026, according to the Wall Street Journal. In investor meetings, it said it plans to expand healthcare and biology AI use cases. The article highlights potential AI-biotech beneficiaries, citing results and guidance for Absci, Recursion, Schrodinger, Twist Bioscience, and Tempus AI, including Tempus Q2 revenue of $382.49M and raised FY guidance to $1.595 to $1.605B.
TWST sentiment & insider activity
Over the past 7 days, alphai's AI scored 3 news stories mentioning TWST (Twist Bioscience Corp). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent TWST coverage spans insider activity, corporate actions and sector analysis.
In the last 30 days, TWST insiders filed 9 SEC Form 4 transactions — no purchases and 9 sales ($18.9M). The most active reporter was Finn Patrick John, President and COO, with 2 filings. 33% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving TWST
This is an insider open-market sale by the CEO, not a new operating or financial disclosure.
This is an insider open-market sale under a pre-arranged 10b5-1 plan, which is typically lower-signal than discretionary selling.
TWST has the clearest fundamental “raise” signal in the text, which can drive near-term repricing.
Near-term momentum is supported by beat-and-raise guidance and a stated path to adjusted EBITDA breakeven, but the $96 offering introduces dilution risk.
This is a routine, pre-planned insider sale disclosure; it may slightly affect sentiment but is not a fundamental catalyst by itself.
alphai scores every news story that mentions TWST with an AI model for sentiment and relevance, and aggregates insider trades from Twist Bioscience Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $TWST
Score
Leproust Emily M. sold $14.2M of TWST
Leproust Emily M. (Chief Executive Officer) sold 113,318 shares of Twist Bioscience Corp (TWST) at $125.16 ($14.18M total) on 2026-08-10 under a Rule 10b5-1 trading plan.
2 min readCHESS ROBERT sold $2.0M of TWST
CHESS ROBERT sold 18,417 shares of Twist Bioscience Corp (TWST) at $110.89 ($2.04M total) on 2026-08-07 under a Rule 10b5-1 trading plan.
1 min read
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
Anthropic is reportedly targeting an IPO in September or early October 2026, according to the Wall Street Journal. In investor meetings, it said it plans to expand healthcare and biology AI use cases. The article highlights potential AI-biotech beneficiaries, citing results and guidance for Absci, Recursion, Schrodinger, Twist Bioscience, and Tempus AI, including Tempus Q2 revenue of $382.49M and raised FY guidance to $1.595 to $1.605B.
6 min read
Twist Bioscience TWST Jumps As Guidance, Targets And Cash Raise Align
Twist Bioscience (TWST) shares rose about 7.9% after Q3 results and guidance. Q3 revenue was $118.4M vs ~$114.5M consensus, with EPS loss widening to ($0.56). Full-year 2026 revenue guidance rose to $456M-$457M and Q4 revenue to $123M-$124M, targeting adjusted EBITDA breakeven. The company priced a $300M offering at $96.
6 min readCho Dennis sold $1.6M of TWST
Cho Dennis (See Remarks) sold 14,205 shares of Twist Bioscience Corp (TWST) at $109.75 ($1.56M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
2 min readTwist Bioscience Corp (TWST): Entry into a Material Definitive Agreement
Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 tm2622018d2_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 TWIST BIOSCIENCE CORPORATION 3,125,000 Shares of Common Stock Underwriting Agreement August 4, 2026 Goldman Sachs & Co. LLC William Blair & Company, L.L.C. Leerink Partners LLC Guggenheim Securities, LLC As Representatives of
3 min readFinn Patrick John sold $246K of TWST
Finn Patrick John (President and COO) sold 2,888 shares of Twist Bioscience Corp (TWST) at $85.32 ($0.25M total) on 2026-08-03.
1 min readLeproust Emily M. sold $435K of TWST
Leproust Emily M. (Chief Executive Officer) sold 5,101 shares of Twist Bioscience Corp (TWST) at $85.32 ($0.44M total) on 2026-08-03.
2 min readTwist Announces Pricing Of $300 Mln Underwritten Upsized Public Offering
Twist Bioscience (TWST) priced an underwritten upsized public offering of 3.12 million shares at $96.00 each, raising about $300 million in gross proceeds. Underwriters received a 30-day option for up to an additional $37.5 million. Proceeds will fund R&D, manufacturing expansion, working capital and general purposes. Closing is expected Aug. 6, 2026.
3 min readTwist Bioscience Q3 Earnings Call Highlights
Twist Bioscience (NASDAQ:TWST) reported Q3 revenue of about $77.3M in the Americas (+30% YoY), $33.6M in EMEA (+9%), and $7.5M in APAC (+26%). Global supply partner revenue was $12.9M. Gross margin was 52.8%. It raised FY2026 revenue guidance to $456M-$457M and forecast Q4 revenue of $123M-$124M.
6 min read